Psoriasis Pathogenesis and the Development of Novel, Targeted Immune Therapies
Explore this paper's citation graph
Summary
Clinical trial data for mAbs against IL‐17 signaling and newer IL‐23p19 antagonists underscore the central role of these cytokines as predominant drivers of psoriatic disease.
- Type
- review
- Published
- 2017-09-01
- Cited by
- 884
- References
- 87
- Access
- Open access
- OpenAlex
- https://openalex.org/W2752721387
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:205615452
Keywords
Psoriasis, Secukinumab, Ixekizumab, Immunology, Medicine
References
- A Disintegrin-like and Metalloprotease (Reprolysin-type) with Thrombospondin Type 1 Motif (ADAMTS) Superfamily: Functions and Mechanisms*
- Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis.
- Effector and regulatory T cell subsets in autoimmunity and tissue inflammation
- Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to self‐DNA
- Angiogenesis drives psoriasis pathogenesis
- Deep Sequencing of the T-cell Receptor Repertoire Demonstrates Polyclonal T-cell Infiltrates in Psoriasis
- Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
- Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation
- Secukinumab in plaque psoriasis--results of two phase 3 trials.
- The risk of mortality in patients with psoriasis: results from a population-based study.
- Insights into gene modulation by therapeutic TNF and IFNgamma antibodies: TNF regulates IFNgamma production by T cells and TNF-regulated genes linked to psoriasis transcriptome.
- Differential expression and regulation of IL-23 and IL-12 subunits and receptors in adult mouse microglia.
- Psoriasis and HLA‐Cw6
- Clearance of severe psoriasis after allogenic bone marrow transplantation.
- SYSTEMIC CONRTICOSTEROIDS AND FOLIC ACID ANATONISTS IN THE TREATMENT OF GENRALIZED PUSTULAR PSOBLASIS EVALUATION AND PROGNOSIS BASED ON THE STUDY OF 104 CASES
- Intraindividual genome expression analysis reveals a specific molecular signature of psoriasis and eczema
- Resident and “inflammatory” dendritic cells in human skin
- Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling.
- Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
Cited by
- Risankizumab for the treatment of moderate to severe psoriasis
- Phase 2, randomized dose‐finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis
- IL-17 May Be a Key Cytokine Linking Psoriasis and Hyperglycemia.
- Therapeutic Effects of Shikonin on Skin Diseases: A Review.
- The Genetic Basis of Psoriasis
- Antagonist Anti-CD28 Therapeutics for the Treatment of Autoimmune Disorders
- Research Techniques Made Simple: Murine Models of Human Psoriasis
- Structural activation of pro-inflammatory human cytokine IL-23 by cognate IL-23 receptor enables recruitment of the shared receptor IL-12Rβ1
- Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis
- Sleep Deficiency and Psoriasis: Implications for Clinical Practice
- Effects of Biologic Therapy on Cardiovascular Disease in Psoriasis
- Psoriasis: A STAT3-Centric View
- Innate lymphoid cells in autoimmunity and chronic inflammatory diseases
- Pharmacokinetics of Tildrakizumab (MK‐3222), an Anti‐IL‐23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects
- Risk of preterm delivery and small-for-gestational-age births in women with autoimmune disease using biologics before or during pregnancy: a population-based cohort study
- The synergistic activities of the combination of tumour necrosis factor‐α, interleukin‐17A and interferon‐γ in epidermal keratinocytes
- Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment
- Yet another step forward!
- Autoimmune Mechanisms of Psoriasis: Pathogenic Role of the IL-23/IL-17 Axis
- Effect of γ-secretase inhibitor on Th17 cell differentiation and function of mouse psoriasis-like skin inflammation
Related papers
- Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.
- Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F
- Targeting of interleukin-17 in the treatment of psoriasis
- Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential
- A New Way to Inhibit IL-17 in Psoriasis: Real-Life Use of Brodalumab Goes Beyond Clinical Trials Expectations
- The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond
- A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
- The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis
- Minimal Physiologically-Based Pharmacokinetic (mPBPK) Metamodeling of Target Engagement in Skin Informs Anti-IL17A Drug Development in Psoriasis
- IL-17 Blockade in Psoriasis.